Skip to content
10-Q

Quarterly Report

Akero Therapeutics, Inc.

0000950170-24-094347

← back to feed
Filed
Aug 9, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 2, 2024 69.43M sh
Cash And Equivalents Q2 2024 · Jun 30, 2024 $310.36M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $234.21M
Current Liabilities Q2 2024 · Jun 30, 2024 $31.17M
Current Liabilities Q2 2024 · Dec 31, 2023 $19.13M
Total Liabilities Q2 2024 · Jun 30, 2024 $66.98M
Total Liabilities Q2 2024 · Dec 31, 2023 $44.97M
Current Assets Q2 2024 · Jun 30, 2024 $776.01M
Current Assets Q2 2024 · Dec 31, 2023 $559.96M
Total Assets Q2 2024 · Jun 30, 2024 $865.04M
Total Assets Q2 2024 · Dec 31, 2023 $580.27M
Shares Diluted Q2 2024 · Jun 30, 2023 51.87M sh
Shares Diluted Q2 2024 · Jun 30, 2023 49.42M sh
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$47.02M
Stockholders Equity Q2 2024 · Jun 30, 2023 $616.44M
Stockholders Equity Q2 2024 · Mar 31, 2023 $306.35M
Stockholders Equity Q2 2024 · Dec 31, 2022 $326.56M
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.60
Eps Diluted Q2 2024 · Jun 30, 2023 −$1.15
Eps Basic Q2 2024 · Jun 30, 2023 −$0.60
Eps Basic Q2 2024 · Jun 30, 2023 −$1.15
Sga Expense Q2 2024 · Jun 30, 2023 $7.64M
Sga Expense Q2 2024 · Jun 30, 2023 $14.61M
Rd Expense Q2 2024 · Jun 30, 2023 $27.99M
Rd Expense Q2 2024 · Jun 30, 2023 $49.77M
Net Income Q2 2024 · Jun 30, 2023 −$31.08M
Net Income Q2 2024 · Jun 30, 2023 −$56.91M
Net Income Q2 2024 · Mar 31, 2023 −$25.83M
Net Income Q2 2024 · Dec 31, 2022 −$112.03M
Operating Income Q2 2024 · Jun 30, 2023 −$35.63M
Operating Income Q2 2024 · Jun 30, 2023 −$64.38M